TLR3 and acute respiratory distress syndrome: These findings provide foundational insights and suggest that a single dose of IV GLN administration after respiratory virus infection may have potential therapeutic significance in mitigating systemic inflammation and modulating ssRNA virus-related TLR-3 pathway-induced acute respiratory distress syndrome or other critical illnesses.